西酞普兰合并利培酮治疗难治性抑郁症的对照研究

A comparative study of escitalopram augmented with resperidone in the treatment of refractory depression

目的探讨西酞普兰合并利培酮治疗难治性抑郁症的安全性和疗效。方法将92例难治性抑郁症患者随机分为两组,研究组采用西酞普兰合并利培酮治疗,对照组单用西酞普兰治疗,两组分别在治疗后第2、4、8、12周末,采用汉密顿抑郁量表(HAMD)和临床总体印象量表(CG I)评定疗效,Asberg抗抑郁剂不良反应量表评定不良反应。结果根据HAMD评分,两组8周末减分率分别为(31.85±12.78),(19.00±11.88),两组12周末减分率分别为(48.46±20.75),(29.54±16.85),两组间差异均具有显著性意义(P<0.05);根据CG I评分,两组8周末评分分别为(2.31±0.95)、(3.15±1.06),两组12周末评分分别为(2.00±1.00)、(2.92±1.19),两组间差异具有显著性意义(P<0.05);药物不良反应两组间无明显差异(P>0.05)。结论西酞普兰合并利培酮治疗难治性抑郁症的疗效好,不良反应无明显增加。。

Objective To study the efficacy and side effects of escitalopram augmented with resperidone in treatment of refractory depression. Methods A total of 92 patients with refractory depression were randomly divided into study group with escitalopram augmented with resperidone and control group with eseitalopram for treatment of 12 weeks. All subjects were assessed with Hamilton Rating Scale for Depression（ HAMD）, Clinical Global Impression（CGI）, Asberg Rating Scale for Side Effects in end of 2th,4th,8th and 12th. Results The rates of decreased scores in HAMD between two groups in end of 8th week were （ 31.85 ± 12. 78 ）, （ 19. 00 ±11.88 ） and in end of 12th week were （ 48.46 ± 20. 75 ）, （ 29. 54 ± 16. 85）. There were significant differences between two groups beth in 8th and 12th weekend（P 〈0. 05）. In the end of Sth week the scores of CGI were（2. 31 ±0. 95） of study group, （3. 15 ± 1.06） of control group and in the end of 12th week （2. 00± 1.00）of study group, （2. 92 ± 1.19）of control group. There were significant differences between two groups（P 〈 0. 05）. There were no significant differences in scores of Asberg Rating Scale for Side Effects between two groups （ P 〉 0. 05）. Conclusion Escitalopram augmented with respefidone is effective in the treatment of refractory depression and doesn＇t increase side effects.